Charles A Gersbach

This inventor holds 21 USPTO granted patents and 43 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Genome Engineering. Top assignees: Duke University, North Carolina State University, University of Utah Research Foundation. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles A Gersbach. Retrieved from https://idiyas.com/inventor/charles-a-gersbach

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 43)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 10 (Patent Applications = 51)

Average Co-Inventor Count = 2.6

ph-index = 9

Forward Citations = 160(Granted Patents)

Company Filing History:

North Carolina State University

patents

1 out of 1,687

University of Utah Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Gene Editing

CRISPR Systems

Epigenome Editing

Duchenne Muscular Dystrophy

Gene Expression

Cell Therapy

RNA-guided Endonucleases

Genetic Correction

Therapeutic Applications

High-throughput Screening

Eukaryotic Cells

Transcriptional Regulation

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12629428 - AAV VECTOR-MEDIATED DELETION OF LARGE MUTATIONAL HOTSPOT FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (2026-05-19),

2. 12509492 - GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES (2025-12-30),

3. 12428631 - CRISPR/Cas9-based repressors for silencing gene targets in vivo and methods of use (2025-09-30),

4. 12215366 - Compositions and methods for epigenome editing (2025-02-04),

5. 12215345 - Compositions and methods for the induction and tuning of gene expression (2025-02-04),

6. 12214056 - Therapeutic applications of CPF1-based genome editing (2025-02-04),

7. 12214054 - Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use (2025-02-04),

8. 11976307 - Genetic correction of mutated genes (2024-05-07),

9. 11970710 - Genome engineering with Type I CRISPR systems in eukaryotic cells (2024-04-30),

10. 11427817 - Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases (2022-08-30),

11. 11421251 - Genome engineering with type I CRISPR systems in eukaryotic cells (2022-08-23),

12. 11319555 - Compositions, systems and methods for cell therapy (2022-05-03),

13. 11155796 - Compositions and methods for epigenome editing (2021-10-26),

14. 10954513 - RNA-guided transcriptional regulation and methods of using the same for the treatment of back pain (2021-03-23),

15. 10745714 - RNA-guided gene editing and gene regulation (2020-08-18),

Title: Charles A. Gersbach: Pioneering Gene Editing Innovator

Introduction: Charles A. Gersbach is a renowned inventor based in Durham, NC, who has made significant contributions to the field of gene editing. With a total of 18 patents to his name, he has been at the forefront of innovations targeting genetic diseases, particularly through advanced therapeutic applications.

Latest Patents: Among his most recent groundbreaking patents are "Therapeutic Targets for the Correction of the Human Dystrophin Gene by Gene Editing and Methods of Use," which focuses on innovative strategies for correcting the dystrophin gene responsible for muscular dystrophies. Additionally, his work on "Therapeutic Applications of CPF1-Based Genome Editing" emphasizes the versatility of the CRISPR/Cpf1 technology in medical applications, further enhancing the field of gene therapy.

Career Highlights: Gersbach has had an illustrious career, greatly influenced by his roles at prestigious institutions like Duke University and North Carolina State University. His research has not only pushed the boundaries of genetic engineering but has also opened new avenues for therapeutic interventions in genetic disorders.

Collaborations: Throughout his career, Gersbach has collaborated with notable professionals in the field, including Isaac B. Hilton and David G. Ousterout. These collaborations have further enriched his research, leading to innovative solutions in gene editing and therapy.

Conclusion: Charles A. Gersbach stands out as a pivotal figure in gene editing innovation. His contributions through numerous patents and collaborations reflect his dedication to advancing medical science and improving the lives of those affected by genetic disorders. As he continues to explore new frontiers in this vital area, his work is expected to have lasting impacts on the future of gene therapy.

Profile summary based on public USPTO records.